Respiratory Monitoring Devices Global Market Report 2023 – By Type (Capnographs, Gas Analyzers, Pulse Oximeters, Peak Flow Meters, Spirometers, Polysomnographs, Others Types), By EndUser (Laboratories, Hospitals, Home Use), By Application (Chronic Obstructive Pulmonary Disease (COPD), Infectious Diseases, Asthma, Other Applications) – Market Size, Trends, And Global Forecast 2023-2032

Anesthesia And Respiratory Devices Market Definition

The anesthesia and respiratory devices market consists of sales of anesthesia and respiratory devices and related services by entities that manufacture such devices used in the diagnosis and treatment of respiratory diseases such as asthma, cystic fibrosis, and acute respiratory distress syndrome. Anesthesia devices are medical devices used to support the administration of anesthetics and medical gases such as nitrous oxide for the temporary induced loss of sensation or awareness. Anesthetics may include analgesia (used for relief from or prevention of pain) and temporary paralysis (used for muscle relaxation). Respiratory devices are used to provide medication or assist a patient who is having difficulty in breathing and cannot achieve adequate oxygen levels to maintain life.

Respiratory devices and equipment (therapeutic and diagnostic) are used to provide medication or assist a patient who is having difficulty in breathing and cannot achieve adequate oxygen levels to maintain life. Patients with respiratory disorders such as asthma, cystic fibrosis, chronic obstructive pulmonary disease, and acute respiratory distress syndrome require respiratory devices. The main types of respiratory devices and equipment are diagnostic devices, therapeutic devices, and monitoring devices. The diagnostic devices are used to diagnose respiratory-related issues. The various therapeutic devices are humidifiers, nebulizers, oxygen concentrators, positive airway pressure (PAP) devices, ventilators, and others. The diagnostic devices involved are spirometer, polysomnographs, and peak flow meters and monitoring devices are pulse oximeters, capnography, and gas analyzers. These provide applications in chronic obstructive pulmonary disease (COPD), asthma, obstructive sleep apnea (OSA), respiratory distress syndrome (RDS), cystic fibrosis, and pneumonia. These are used by hospitals, clinics, home care settings, and ambulatory service centres. The global respiratory devices and equipment (therapeutic and diagnostic) market is segmented - 1) By Type: Diagnostic devices, Therapeutic devices, Monitoring devices 2)By End User: Hospitals, Clinics, Homecare settings, Ambulatory service centers, 3) By Therapeutic Devices: Humidifiers, Nebulizers, Oxygen concentrators, Positive Airway Pressure (PAP) Devices, Ventilators, Other Therapeutic Devices 4) By Diagnostic Devices: Spirometer, Polysomnographs, Peak Flow Meters 5) By Monitoring Devices: Pulse oximeters, Capnographs, Gas analyzers 6) By Application: Chronic Obstructive Pulmonary Disease (COPD), Asthma, Obstructive Sleep Apnea (OSA), Respiratory Distres Syndrome (RDS), Cystic Fibrosis, Pneumonia The global respiratory devices and equipment (therapeutic and diagnostic) market size will grow from $29.09 billion in 2022 to $32.76 billion in 2023 at a compound annual growth rate (CAGR) of 12.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global respiratory devices and equipment (therapeutic and diagnostic) is expected to grow to $50.54 billion in 2027 at a CAGR of 11.5%. The global respiratory devices and equipment (therapeutic and diagnostic) market will be driven by the increase in diseases such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and lung cancer. Growth in the geriatric population, tobacco consumption, allergens, and air pollutants increase the prevalence of respiratory diseases, in turn driving the global therapeutic respiratory devices market. According to World Health Organisation,4.9 million people die due to tobacco consumption, and smoking causes chronic obstructive pulmonary diseases (1 million deaths annually), cardiovascular and respiratory diseases (1.7 million deaths annually), and lung cancer (0.85 million deaths annually). According to an Italian journal, COPD in the U.S. is estimated to be 10% in the population aged 75 years or over. According to Asthma UK, 5.4 million people in the UK are currently receiving treatment for asthma out of these 1.1 million are children and 4.3 million are adults. Major players in the respiratory devices and equipment (therapeutic and diagnostic) market are Smiths Medical, Philips Healthcare, GE Healthcare, Chart Industries, Invacare Corporation, Fisher & Paykel Healthcare Limited, ResMed, Dragerwerk AG, Medtronic PLC., Masimo corp., and CareFusion Corporation. A longer duration of time taken in the approval process of the respiratory devices is restricting the respiratory devices and equipment market growth. Before a new respiratory device is introduced to the market, it takes 7.2 months for the FDA approval process, which adds to development costs to be borne by device manufacturers, thus acting as a restraint hindering the market growth. For instance, FDA reviews about 4,000 submissions every year and takes about 3 to 6 months in clearing most of them. In addition to this, to reduce incidences associated with the respiratory devices and ensure that the devices are safe and have the least adverse reactions, the Medicines and Healthcare products Regulatory Agency (MRHA), UK regulates and monitors the devices by restricting devices for use and sending field safety notice to correct the devices. These stringent approval processes and regulatory policies may impact the respiratory devices and equipment (therapeutic and diagnostic) market market. Companies in the respiratory devices and equipment (therapeutic and diagnostic) market are increasingly investing in enhanced mechanical ventilators for efficient patient management. These mechanical ventilators use artificial intelligence to improve patient management by examining, analyzing, integrating, and incorporating data from extensive sources. These AI-enabled devices ensure consistency even in the absence of expert personnel, improve patients' treatment, limit clinical mistakes, and predict prolonged mechanical ventilation by using artificial intelligence techniques. Some of the major companies offering intelligent mechanical ventilators such as Hamilton Medical AG, Koninklijke Philips N.V., and others. In June 2021, Philips respironics issued a voluntary recall notification after discovering potential health risks related to CPAP, BiPAP and Mechanical ventilator devices. The notification also included a field safety notice for users who did not intend to send the devices for repair. Asia-Pacific was the largest region in respiratory devices and equipment (therapeutic and diagnostic) market in 2022. Western Europe was the second-largest region in the respiratory devices and equipment (therapeutic and diagnostic) market report. The regions covered in the respiratory devices and equipment (therapeutic and diagnostic) analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory devices and equipment (therapeutic and diagnostic) market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, USA, and Australia. The respiratory devices and equipment (therapeutic and diagnostic) market consists of sales of instruments such as humidifiers, nebulizers, oxygen concentrators, positive airway pressure (PAP) devices, ventilators, spirometer, polysomnographs, peak flow meters, pulse oximeters, capnographs, and gas analyzers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The respiratory devices and equipment (therapeutic and diagnostic) market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The respiratory devices and equipment (therapeutic and diagnostic) market research report is one of a series of new reports from The Business Research Company that provides respiratory devices and equipment (therapeutic and diagnostic) market statistics, including respiratory devices and equipment (therapeutic and diagnostic) industry global market size, regional shares, competitors with a respiratory devices and equipment (therapeutic and diagnostic) market share, detailed respiratory devices and equipment (therapeutic and diagnostic) market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory devices and equipment (therapeutic and diagnostic) industry. The respiratory devices and equipment (therapeutic and diagnostic) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary patient monitoring equipment refers to a type of devices and instruments that continuously track and record changes in patient wellbeing, monitor animals' respiration, blood pressure, and other vital signs, and provide warning systems. These systems are used to continuously monitor the animals to detect diseases at early stages to prevent any risks. The main types of veterinary patient monitoring equipment are cardiac monitoring devices, respiratory monitoring devices, remote patient monitoring devices, multi-parameter monitoring devices, neuromonitoring devices, and other products. The cardiac monitoring devices refer to the devices that deal with animal cardiac diseases. These are used for animals such as small companion animals, large companion animals, wild animals, zoo animals, aquatic animals, and exotic animals. Veterinary patient monitoring equipment is used in veterinary hospitals, veterinary clinics, and veterinary research centers. The global veterinary patient monitoring equipment market is segmented - 1) By Product: Cardiac Monitoring Devices, Respiratory Monitoring Devices, Remote Patient Monitoring Devices, Multi-Parameter Monitoring Devices, Neuromonitoring Devices, Other Products 2) By End User: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Centers 3) By Animal: Small Companion Animals, Large Companion Animals, Wild Animals, Zoo Animals, Aquatic Animals, Exotic Animals The global veterinary patient monitoring equipment market size will grow from $0.42 billion in 2022 to $0.45 billion in 2023 at a compound annual growth rate (CAGR) of 7.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global veterinary patient monitoring equipment market size is expected to grow from $0.58 billion in 2027 at a CAGR of 6.4%. Major players in the veterinary patient monitoring market are Smiths Group plc; Hallowell Engineering & Manufacturing Corporation; DRE Veterinary; Digicare Biomedical Technology Inc.; Midmark Corporation; Medtronic PLC.; Jorgensen Laboratories; Vetland Medical Sales and Services LLC; Jorgen Kruuse A/S; Mila International Inc.; and Mindray Medical International Limited. An increase in the prevalence rate of diseases among animals serves as one of the major drivers for the veterinary patient monitoring equipment market. An increase in the incidence of diseases in livestock and companion animals will require monitoring equipment to diagnose the diseases in animals. For instance, according to the Banfield Pet Hospital's 2020 Veterinary Emerging Topics (VET) Report, more than 50% of the dogs at 1,000 hospitals in 2019 were overweight or obese. Overweight pets are more likely to suffer from joint disease, respiratory disease, and other preventable conditions. The increase in the prevalence rate of diseases for animals results in an increased demand for enhanced veterinary patient monitoring equipment market. Veterinary patient monitoring equipment is highly expensive. The cost of equipment will be a significant expense for a veterinary clinic or hospital. For instance, the average wearable device ranges from $50 to $100 and will likely have a recurring software as a service (SaaS) fee to store and retrieve an animal’s health data analytics. These expenses hinder the growth of the veterinary patient monitoring equipment market. Veterinarians and pet or cattle owners are shifting to wearable technology to keep track of animal behavior. Wearable technology is smart electronic devices that are worn on the body or integrated with clothing or accessories and monitor body temperature, behavior, and movement. These wearable monitoring devices provide timely insights regarding the overall health of the animal and help the veterinarian provide an appropriate diagnosis for the animal. For instance, Vetrax, a wearable sensor worn on a dog’s collar, enables clinicians and pet owners to monitor aspects of an animal’s behaviour when they are unsupervised. According to a report by Veterinary Practice News, 83% of pet owners are satisfied with the use of wearable technology and 68% find it an effective way of monitoring the weight and diabetes of their pets. The veterinary patient monitoring equipment market is regulated by government agencies such as the European Medicines Agency (EMA), USFDA (the US Food and Drug Administration), and others. The EMA should certify the medical devices before they are marketed. The EMA verifies the safety and quality of the devices before they can be certified and approved for use throughout the European Union. The EMA requires all devices to comply with the regulations stated under Directive 2001/82/EC and Regulation (EC) No. 726/2004. In August 2020, Merck Animal Health, a US-based company specializing in veterinary products, technologies, and services, acquired IdentiGEN Ltd. for an undisclosed amount. Through this acquisition, Merck offers animal monitoring for food producers, processors, and retailers who are searching for precise and comprehensive animal traceability solutions that offer full accountability as well as increased transparency, food quality, and sustainability for consumers. In combination with Merck's current identification and monitoring technology, which provides real-time, actionable data and insights to aid in, improve, or enhance animal management and health outcomes, the addition of specialized digital technology to our portfolio of medications, vaccines, and services offers comprehensive solutions to help advance animal health. IdentiGEN Ltd. is a land-based company pioneering in DNA-based analysis and diagnostics for animal health monitoring. North America was the largest region in the veterinary patient monitoring market in 2022. Asia-Pacific was the second-largest region in the global veterinary patient monitoring market share. The regions covered in the global veterinary patient monitoring equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the veterinary anesthesia equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, and USA. The veterinary patient monitoring equipment market consists of sales of bedside patient monitoring systems, renal patient monitoring devices, circulatory system patient monitoring devices, and obesity patient monitoring devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The veterinary patient monitoring equipment research report is one of a series of new reports from The Business Research Company that provides veterinary patient monitoring equipment statistics, including veterinary patient monitoring equipment industry global market size, regional shares, competitors with veterinary patient monitoring equipment shares, detailed veterinary patient monitoring equipment segments, market trends and opportunities, and any further data you may need to thrive in the veterinary patient monitoring equipment industry. This veterinary patient monitoring equipment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Respiratory disposables are used to interface respiratory devices with patients, such as ventilators, nebulizers, and oxygen therapy devices. The main types of respiratory disposables market are masks, tubes, inhalers, and others. A mask is a piece of cloth or other material that is personal protective equipment intended for medical purposes. These are used for disease indications such as asthma, a chronic obstructive pulmonary disorder, tuberculosis, lung cancer, and other chronic respiratory diseases. The applications involved in adult, pediatric, and neonatal. The various end-users are hospitals, clinics, ambulatory care centres, and others. The global respiratory disposables market is segmented - 1) By Type: Masks, Tubes, Inhalers, Other Types 2) By End User: Hospitals, Clinics, Ambulatory Care Centers, Other End Users 3) By Disease Indications: Asthma, Chronic Obstructive Pulmonary Disorder, Tuberculosis, Lung Cancer, Other Chronic Respiratory Diseases 4) By Application: Adult, Pediatric & Neonatal The global respiratory disposables market size will grow from $2.77 billion in 2022 to $3.07 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global respiratory disposables is expected to grow to $4.41 billion in 2027 at a CAGR of 9.5%. The high prevalence rate of respiratory disposables market globally is driving the respiratory disposables market. Excessive smoking, exposure to toxic materials, adverse climate conditions, and air pollution are some of the main causes which are leading to a rise in respiratory diseases such as asthma, lung cancer, Chronic Obstructive Pulmonary Disease (COPD), and obstructive sleep apnea (OSA). According to a study, around 65 million people suffer from chronic obstructive pulmonary disease (COPD) and around 3 million people die every year because of this disease. It was also reported that around 334 million people suffer from asthma diseases caused by air pollution as well as tobacco smoke, toxic disposable devices. These factors are increasing the demand for the treatment of respiratory ailments, thus driving the respiratory disposables market. Major players in the respiratory disposables market are Fisher & Paykel, Becton Dickinson Company, Ambu A/S, Smiths Medical, Armstrong Medical, Teleflex, Philips Respironics, Besmed, ResMed, and Dynarex. The respiratory disposables market is being restrained due to stringent regulatory policies. Regulatory agencies and governments across various countries are imposing stringent restrictions on product approval and launch, this is limiting the market growth. For instance, FDA banned Amphastar Pharmaceutical’s Primatene product, an albuterol CFC inhaler for asthma because ozone-depleting chlorofluorocarbon (CFC) propellants have depleted the ozone layer. The FDA rejected Amphastar’s first attempt to bring a reformulated version of Primatene mist to market. The FDA rejected another application for Primatene Mist. Which resulted in a rise in development costs and potential sales loss due to delays in product launch, thus restraining the Respiratory disposables market. Rapid advances in technology are driving innovation in respiratory disposable manufacturing. Areas of particular development are likely to be AIR gel technology, wearable technologies, and 3D printing technology. These technologies are being used in the manufacturing of respiratory disposables, resulting in higher productivity, lower costs, and higher margins. Companies in this market are increasingly focusing on AIR gel technology, in which gel is incorporated into the bag on the edges of the mask which helps to the protection of the skin and creates a bridge to minimize the irritation of the skin and for effective sealing. For example, Vyair medical prepared Veraseal 2 disposable mask, used for acute care with AIR gel technology and advantage of vented and non-vented versions. Similarly, Sleepnet prepared Mojo ventilation masks with Airgel technology. In the USA, occupational safety and health administration (OSHA) regulates all respiratory medical equipment, guidelines for which are specified in 29 CFR 1910. 134. Under OSHA, the national institute for occupational safety and health/national personal protective technology laboratory (NIOSH/ NPPTL) provides a market approval certificate and FDA approves the product for marketing. Before market approval, all the medical devices should be analyzed appropriately by performing a compatibility test within a hospital environment. They are tested on an Electrical bench and Non-clinical performance testing is also required. Moreover, proper software verification, validation, and hazard analysis must be performed. Labels on the devices are required to include the purpose of the device. In 2021, Medline a Netherland-based medical device company acquired the Hudson RCI brand of respiratory consumables from Teleflex. The acquisition helps Medline's offerings, enlarging the respiratory environment with the highly regarded Hudson RCI products and opening extra opportunities for development and help to customers. Teleflex is a US-based company global provider of medical technologies designed to develop the health and quality of people's lives. Asia-Pacific was the largest region in the global respiratory disposables and equipment market in 2022. Western Europe was the second-largest region in the respiratory disposables market report. The regions covered in the respiratory disposables analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory disposables market include Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The respiratory disposables market consists of sales of instruments such as disposable resuscitators, disposable masks, nasal cannulas, tracheostomy tubes, and other consumables and accessories. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The respiratory disposables market research report is one of a series of new reports from The Business Research Company that provides respiratory disposables market statistics, including respiratory disposables industry global market size, regional shares, competitors with a respiratory disposables market share, detailed respiratory disposables market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory disposables industry. The respiratory disposables market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug delivery devices are used to deliver specific drugs to a specific part of the body to cure diseases. Drug delivery devices used in various patient care settings, such as hospitals, diagnostic centers, clinics, and home care settings, are included in this market. The main routes of administration of drug delivery devices is oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, and implantable drug delivery. Oral drug delivery is a route of drug delivery in which a tablet or capsule is administered into the alimentary canal of a human being. The patient care settings is hospitals, diagnostic centres, ambulatory surgery centres/clinics, home care settings, and others. The various applications involved are cancer, infectious diseases, respiratory diseases, diabetes, cardiovascular diseases, autoimmune diseases, central nervous system disorders, and others. The global drug delivery devices market is segmented - 1) By Route Of Administration: Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Transmucosal Drug Delivery, Implantable Drug Delivery 2) By Patient Care Setting: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Home Care Settings, Other Patient Care Settings 3) By Application: Cancer, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders, Other Applications The global drug delivery devices market size will grow from $81.13 billion in 2022 to $87.65 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global drug delivery devices is expected to grow from $115.09 billion in 2027 at a CAGR of 7.0%. The rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer and other diseases is expected to drive the drug delivery devices market. According to the world health organization (WHO), by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and 71% of deaths due to ischemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. There are various routes of drug administration for medical drugs. The selection of the route depends on three factors - the effect desired; the type of the disease and the type of the product. Currently, the development of new drug delivery systems plays a major role in the pharmaceutical industry. Research and development (R&D) in drug delivery are increasing throughout the world due to the increasing prevalence of these diseases. Most pharmaceutical companies are focusing on multiple drug delivery technologies for creating excellent advantages and better outcomes for their marketed products. Hence, the increasing prevalence of chronic diseases is resulting in increased consumption of therapeutic drugs and therapies, and this factor is expected to act as a driver for the growth of the drug delivery devices market. Major players in the drug delivery devices market are F. Hoffmann-La Roche Ltd., 3M Company, Pfizer Inc., Baxter International, BD, Novartis AG, Gerresheimer AG, Johnson & Johnson Services, Inc., Bayer AG, and GlaxoSmithKline PLC. The regulatory changes related to medical devices is expected to restrain the growth of the drug delivery devices market. The companies operating in the market are required to adapt according to the changes in the regulatory framework, which may limit business at the bottom line. Also, companies will have to bear the heavy cost of adapting to the changing regulatory framework. Also, the sudden changes in the regulatory framework related to medical devices can result in losses, fines, and penalties at a global level. The new MDSAP will come into effect in 2020 and is adopted by regulators in the US, Canada, Japan, Brazil, and Australia. Following the changes, in Canada, all the medical device manufacturers including drug delivery products manufacturers, will have to comply with the requirements of MDSAP and are required to submit the MDSAP reports to the regulatory body in order to obtain or maintain the device licenses, resulting in high costs and time loss. Thus, the growth of the drug delivery devices market is limited by the regulatory changes related to medical devices. The microneedle (MN), is a highly efficient and versatile medical device technology, due to its prominent properties including painless penetration, low cost, excellent therapeutic efficacy, and relative safety. The major players operating in the global microneedle drug delivery system include 3M, Vetter Pharma International GmbH, nano Biosciences LLC., Nano Pass and more. The microneedles are fabricated using biodegradable polymers in which drugs or vaccines are encapsulated in the microneedles. Once, the microneedles dissolve in the skin, the drug gets released. This novel delivery method allows a wider variety of molecules to pass the skin’s barrier, thus allowing the transdermal delivery to be applied to a large range of clinical applications, including diabetes, severe osteoporosis, and influenza vaccination. Companies in the drug delivery devices market are collaborating with other companies within the industry in order to strengthen their product portfolio as well as expand their footprint across different geographies. For example, in October 2022, Nemera, a French pharmaceuticals company, partnered with Zollner Elektronik AG to develop electronic drug delivery systems. Zollner would provide its design, development, and manufacturing capabilities to help Nemera develop electronic drug delivery system. In August 2020, Sulzer, a Swiss-based engineering and manufacturing firm acquired Haselmeier GmbH for $118m. The acquisition of Haselmeier will allow Sulzer to complement its healthcare portfolio, in addition to leveraging its APS expertise in precision injection moulding to expand its presence in the drug delivery devices market. Haselmeier GmbH, a Swiss-German drug delivery device developer and manufacturer. North America was the largest region in the drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the drug delivery devices market report. The regions covered in the drug delivery devices industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The drug delivery devices market consists of sales of instruments such as smart pills, inhalers and nebulizers, drug-eluting stents, safety syringes, and transdermal patches. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides drug delivery devices market statistics, including drug delivery devices industry global market size, regional shares, competitors with a drug delivery devices market share, detailed drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the drug delivery devices industry. This drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical Drugs And Biologics Logistics Market Definition

The pharmaceutical drugs and biologics market consists of sales of pharmaceutical drugs and biologics logistics services by entities (organizations, sole traders and partnerships) that provide pharmaceutical drugs and biologics logistics services. Pharmaceutical drugs and biologics logistics is the logistics of pharmaceutical and biologic drugs from the manufacturer to the end-user. It includes transportation, warehousing, inventory management and other logistics functions.

Medical Devices Market Definition

The medical devices market consists of sales of medical equipment or devices and related services by entities (organizations, sole traders and partnerships) that manufacture medical equipment or devices which are used in the diagnosis, treatment and monitoring of medical conditions. The medical device industry includes establishments that manufacture medical equipment or devices such as in-vitro diagnostic devices, diagnostic imaging equipment, dental equipment and supplies, ophthalmic devices, cardiovascular devices, hospital supplies and other medical devices.

High-potency APIs refer to the substances that, at very low doses, cause a biological response. Traditionally, cytotoxic substances and sex hormones like estrogen are used as examples of HPAPIs. Compared to standard APIs, highly potent active pharmaceutical ingredients HP (high potency) APIs market are nonetheless effective at considerably lower dosage levels, but their potency poses unique handling issues. The main types of HP (high potency) APIs market are innovative HPAPI and generic HPAPI. The various types of synthesis include synthetic HPAPI and biotech HPAPI that are used for therapeutic applications such as oncology, hormonal disorders, glaucoma, and other therapeutic applications (respiratory disorders, CVD, diabetes, cosmetology, and erectile dysfunction). Glaucoma is a group of eye diseases that affect the optic nerve, which is essential for good vision. The global HP (high potency) APIs market is segmented - 1) By Type: Innovative HPAPI, Generic HPAPI 2) By Synthesis Type: Synthetic HPAPI, Biotech HPAPI 3) By Therapeutic Application: Oncology, Hormonal Disorder, Glaucoma, Other Therapeutic Applications (Respiratory Disorders, CVD, Diabetes, Cosmetology, and Erectile Dysfunction) The global HP (high potency) APIs market size grew from $24.53 billion in 2022 to $26.65 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global high potency APIs is expected to grow from $36.14 billion in 2027 at a CAGR of 7.9%. The rising number of cancer cases coupled with increasing sales of cancer drugs contributed to the growth of the HP (high potency) APIs market. The rising incidence of cancer is resulting in increasing R&D for anticancer drugs which in turn is propelling the demand for the market. According to the World Health Organization’s International Agency for Research on Cancer (IARC) report, the cancer burden is expected to increase by 29.5 million new cases and 16.4 million deaths by 2040, globally. Moreover, 70% of deaths from cancer occur in middle and low-income countries. Therefore, the growing incidence of cancer cases is projected to upsurge revenues for the HP (high potency) APIs market growth. Major players in the HP (high potency) APIs market are Eli Lily and Company, Novartis AG, Bristol-Myers Squibb Company, Roche Diagnostics Ltd., Sanofi, Hospira Inc., BASF SE, Covidien PLC., Boehringer Ingelheim GmbH, and Merck & Co. Inc., Sigma Aldrich Corporation, Bayer AG, Carbogen Amcis AG, Lonza, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Mylan Inc., AbbVie, AstraZeneca PLC., and GlaxoSmithKline PLC. High investment requirements are anticipated to restrain the growth of the HP (high potency) APIs market over the coming years. The HP (high potency) APIs market are cytotoxic, which is harmful to human cells. Moreover, they carry significant handling challenges including the requirement for specialized equipment to avoid cross-contamination, product protection, and ensure environment and operator safety. Additionally, the requirement for appropriate process design and the constant evolution of technologies and industry standards, and specialized containment facilities to facilitate the safety of the employees require huge financial support. Therefore, large investment requirement acts as a major challenge for the growth of the HP (high potency) APIs market. The companies dealing in the HP (high potency) APIs market are focusing on strategies such as production facility expansion and mergers and acquisitions to maintain their position in the competitive business environment. For instance, in June 2022, MilliporeSigma, a US-based global life science business, opened the doors to its $65 million facility for the production of high-potency active pharmaceutical ingredients (HPAPI), with an emphasis on cancer treatments. In January 2020, Piramal Pharma Solutions (PPS) declared expenditure of $19 million to enhance its operation in Aurora, Ontario, Canada, with an additional 975 m2 of production space in a new wing for API production, including the production of HPAPI for potent compounds down to an OEL of 1 mcg/m3. In December 2021, SK Capital Partners, a US-based private investment firm, acquired a majority shareholding in SEQENS for an undisclosed amount. Through this acquisition, SEQENS is better positioned as a more potent and concentrated participant in the international markets for specialised ingredients and pharmaceutical solutions. Wavelength Pharmaceuticals, an existing SK Capital portfolio business that is a global manufacturer and developer of active medicinal ingredients, and SEQENS engaged in a combination concurrent with the acquisition. SEQENS is a France-based developer and manufacturer of custom High-Potency APIs. North America was the largest region in the global HP (high potency) APIs market in 2022. Middle East is expected to be the fastest growing region in the HP (high potency) APIs market report during the forecast period. The regions covered in the HP (high potency) APIs industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the HP (high potency) APIs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The market consists of sales of cytotoxic compounds and sex hormones. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The HP (high potency) APIs market research report is one of a series of new reports from The Business Research Company that provides HP (high potency) APIs market statistics, including HP (high potency) APIs industry global market size, regional shares, competitors with an HP (high potency) APIs market share, detailed HP (high potency) APIs market segments, market trends and opportunities, and any further data you may need to thrive in the HP (high potency) APIs industry. This HP (high potency) APIs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.